Behavioral and psychological symptoms of dementia (BPSD) affect patients’ and caregivers’ well-being. Cannabinoids may offer a promising therapeutic option for managing BPSD.
Aims:
This systematic review aims to explore the strengths of using this class of substances in the context of dementia care.
Methods:
We conducted a comprehensive search across Embase Ovid, PubMed, Cochrane Library, APA PsycInfo, and Web of Science, identifying 1839 studies, with 14 selected for full review. Quality was assessed using the Newcastle–Ottawa and the modified Jadad Scales.
Results/Outcomes:
Ten studies (278 participants) were finally included. They showed cannabinoids helped reduce agitation and nocturnal disturbances.
Conclusions/Interpretation:
In conclusion, cannabinoids show promise in managing BPSD in dementia, with good tolerability and safety. Further studies could solidify these findings.
AbateGUbertiDTambaroS (2021) Potential and limits of cannabinoids in Alzheimer’s disease therapy. Biology10(6): 542.
2.
AhmedAIAvan den ElsenGAHColbersA, et al. (2015) Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. Psychopharmacology232(14): 2587–2595.
3.
AnandAKhuranaPChawlaJ, et al. (2018) Emerging treatments for the behavioral and psychological symptoms of dementia. CNS Spectrums23(6): 361–369.
4.
AsoEFerrerI (2014) Cannabinoids for treatment of Alzheimer’s disease: Moving toward the clinic. Frontiers in Pharmacology5: 37.
5.
BaharudinADDinNCSubramaniamP, et al. (2019) The associations between behavioral-psychological symptoms of dementia (BPSD) and coping strategy, burden of care and personality style among low-income caregivers of patients with dementia. BMC Public Health19(Suppl 4): 447.
6.
BahjiAMeyyappanACHawkenER (2020) Cannabinoids for the neuropsychiatric symptoms of dementia: A systematic review and meta-analysis. Canadian Journal of Psychiatry65(6): 365–376.
7.
BallardCLoweryKPowellI, et al. (2000) Impact of behavioral and psychological symptoms of dementia on caregivers. International Psychogeriatrics12(S1): 93–105.
8.
BallardCWaiteJ (2006) The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. The Cochrane Database of Systematic Reviews2006(1): CD003476.
9.
BeeriMSWernerPDavidsonM, et al. (2002) The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer’s disease patients. International Journal of Geriatric Psychiatry17(5): 403–408.
10.
BhuniaSKolishettiNAriasAY, et al. (2022) Cannabidiol for neurodegenerative disorders: A comprehensive review. Frontiers in Pharmacology13: 989717.
11.
Bosnjak KuharicDMarkovicDBrkovicT, et al. (2021) Cannabinoids for the treatment of dementia. The Cochrane Database of Systematic Reviews9(9): CD012820.
12.
BroersBBianchiF (2024) Cannabinoids for behavioral symptoms in dementia: An overview. Pharmacopsychiatry57(3): 160–168.
13.
BroersBPatàZMinaA, et al. (2019) Prescription of a THC/CBD-based medication to patients with dementia: A pilot study in Geneva. Medical Cannabis and Cannabinoids2(1): 56–59.
14.
ClarkHDWellsGAHuëtC, et al. (1999) Assessing the quality of randomized trials: Reliability of the Jadad scale. Controlled Clinical Trials20(5): 448–452.
15.
CloakNAl KhaliliY (2024) Behavioral and psychological symptoms in dementia. In: StatPearls. Treasure Island, FL: StatPearls Publishing.
16.
CoorayRGuptaVSuphiogluC (2020) Current aspects of the endocannabinoid system and targeted THC and CBD phytocannabinoids as potential therapeutics for Parkinson’s and Alzheimer’s diseases: A review. Molecular Neurobiology57(11): 4878–4890.
17.
CristinoLBisognoTDi MarzoV (2020) Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nature Reviews. Neurology16(1): 9–29.
18.
EubanksLMRogersCJBeuscherAE, et al. (2006) A molecular link between the active component of marijuana and Alzheimer’s disease pathology. Molecular Pharmaceutics3(6): 773–777.
19.
HerrmannNRuthirakuhanMGallagherD, et al. (2019) Randomized placebo-controlled trial of nabilone for agitation in Alzheimer’s disease. The American Journal of Geriatric Psychiatry27(11): 1161–1173.
20.
HodgesELAshpoleNM (2019) Aging circadian rhythms and cannabinoids. Neurobiology of Aging79: 110–118.
21.
IringARuisanchezÉLeszl-IshiguroM, et al. (2013) Role of endocannabinoids and cannabinoid-1 receptors in cerebrocortical blood flow regulation. PLoS One8(1): e53390.
22.
KalesHCGitlinLNLyketsosCG (2014) Management of neuropsychiatric symptoms of dementia in clinical settings: Recommendations from a multidisciplinary expert panel. Journal of the American Geriatrics Society62(4): 762–769.
23.
LiSHuangYYuL, et al. (2023) Impact of the cannabinoid system in Alzheimer’s disease. Current Neuropharmacology21(3): 715–726.
24.
LiuCSChauSARuthirakuhanM, et al. (2015) Cannabinoids for the treatment of agitation and aggression in Alzheimer’s disease. CNS Drugs29(8): 615–623.
25.
LuchiniCStubbsBSolmiM, et al. (2017) Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale. World Journal of Meta-Analysis5(4): 80.
26.
MahlbergRWaltherS (2007) Actigraphy in agitated patients with dementia. Monitoring treatment outcomes. Zeitschrift Fur Gerontologie Und Geriatrie40(3): 178–184.
27.
NavarroCEPérezJC (2024) Treatment of neuropsychiatric symptoms in Alzheimer’s disease with a cannabis-based magistral formulation: An open-label prospective cohort study. Medical Cannabis and Cannabinoids7(1): 160–170.
28.
NicholsESteinmetzJDVollsetSE, et al. (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019. The Lancet Public Health7(2): e105–e125.
29.
OutenJDBurhanullahMHVandreyR, et al. (2021) Cannabinoids for agitation in Alzheimer’s disease. The American Journal of Geriatric Psychiatry29(12): 1253–1263.
30.
PautexSBianchiFDaaliY, et al. (2022) Cannabinoids for behavioral symptoms in severe dementia: Safety and feasibility in a long-term pilot observational study in nineteen patients. Frontiers in Aging Neuroscience14: 957665.
31.
ReggioPH (2010) Endocannabinoid binding to the cannabinoid receptors: What is known and what remains unknown. Current Medicinal Chemistry17(14): 1468–1486.
32.
SeitzDPAdunuriNGillSS, et al. (2011) Antidepressants for agitation and psychosis in dementia. The Cochrane Database of Systematic Reviews2: CD008191.
33.
SteinbergMShaoHZandiP, et al. (2008) Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: The Cache County Study. International Journal of Geriatric Psychiatry23(2): 170–177.
34.
StellaFValiengoLCLde PaulaVJR, et al. (2021) Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: A systematic review. Trends in Psychiatry and Psychotherapy43(4): 243–255.
35.
StroupDFBerlinJAMortonSC, et al. (2000) Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA283(15): 2008–2012.
36.
TampiRRTampiDJBalachandranS, et al. (2016) Antipsychotic use in dementia: A systematic review of benefits and risks from meta-analyses. Therapeutic Advances in Chronic Disease7(5): 229–245.
37.
TimlerABulsaraCBulsaraM, et al. (2023) Examining the use of cannabidiol and delta-9-tetrahydrocannabinol-based medicine among individuals diagnosed with dementia living within residential aged care facilities: Results of a double-blind randomised crossover trial. Australasian Journal on Ageing42(4): 698–709.
38.
TrojanVLandaLŠulcováA, et al. (2023) The Main Therapeutic Applications of Cannabidiol (CBD) and its potential effects on aging with respect to Alzheimer’s disease. Biomolecules13(10): 1446.
39.
van den ElsenGAHAhmedAIAVerkesR-J, et al. (2015) Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial. Neurology84(23): 2338–2346.
40.
VolicerLStellyMMorrisJ, et al. (1997) Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. International Journal of Geriatric Psychiatry12(9): 913–919.
41.
WaltherSMahlbergREichmannU, et al. (2006) Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology185(4): 524–528.
42.
WoodwardMRHarperDGStolyarA, et al. (2014) Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. The American Journal of Geriatric Psychiatry22(4): 415–419.
43.
ZhangH-YShenHGaoM, et al. (2021) Cannabinoid CB(2) receptors are expressed in glutamate neurons in the red nucleus and functionally modulate motor behavior in mice. Neuropharmacology189: 108538.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
